Delaying type 1 diabetes progression: major trial readouts to watch in 2023

In November 2022, a major breakthrough occurred when Provention’s Tzield (teplizumab), an anti-CD3 monoclonal antibody, became the first and only drug approved for delaying the onset of type 1 diabetes. In 2023, four more trials will shed light on Tzield and three experimental therapies for the chronic autoimmune disease: Diamyd Medical’s gamma-aminobutyric acid (GABA), Imcyse’s IMCY-0098, and ProKidney’s renal autologous cell therapy (REACT).